Skip to content
Smart Scholars🛡 Scholar Shield🏛 Research Integrity Desk🧩 Portfolio Console📰 Journals🔧 DOI MembersTools🔎 Journal AuditGI GetIndexedDr DOI Doctor

Cite this DOI

10.46243/jst.2025.v10.i08.pp60-65 · Therapeutic Failures in Adult Patients Treated with Artemether-Lumefantrine: A Dual-Sector Analytical Study

APA (7th edition)

M.Kishore Babu, B.Sandhya Rani, I. Triveni, & B.Revathi (2025). Therapeutic Failures in Adult Patients Treated with Artemether-Lumefantrine: A Dual-Sector Analytical Study. *Journal of Science & Technology*, *10*(08), 60–66. https://doi.org/10.46243/jst.2025.v10.i08.pp60-65

⬇ text Italics are shown as *asterisks* in plain text — the journal or book title and the volume.

BibTeX

@article{mkishorebabu2025therapeutic,
  author    = {M.Kishore Babu and B.Sandhya Rani and I. Triveni and B.Revathi},
  title     = {{Therapeutic Failures in Adult Patients Treated with Artemether-Lumefantrine: A Dual-Sector Analytical Study}},
  journal   = {Journal of Science \& Technology},
  year      = {2025},
  month     = {aug},
  volume    = {10},
  number    = {08},
  pages     = {60--66},
  publisher = {Longman Publishers},
  issn      = {2456-5660},
  doi       = {10.46243/jst.2025.v10.i08.pp60-65},
  url       = {https://doi.org/10.46243/jst.2025.v10.i08.pp60-65},
  language  = {en},
  abstract  = {Artemether-Lumefantrine medication is becoming less effective in treating simple cases of malaria in many places where the disease is prevalent. Worldwide, plasmodium falciparum and plasmodium vivax parasite tolerance, recrudescence, and resistance are on the rise. Our objective was to assess the rate of Artemether-Lumefantrine (Coartem) treatment failure in persons presenting with uncomplicated malaria at health facilities. From April 1, 2022, to June 30, 2022, 166 patients with positive malaria test results attended health facilities as part of this descriptive cross-sectional research. A total of 9.6\% of malaria patients did not show improvement after receiving corticosteroids; 6.0\% had plasmodium falciparum, 2.4\% plasmodium vivax, and 1.2 had a mixed infection. Among those who did not take the medication with the fatty meal, 31\% tested positive for malaria after two weeks of receiving coartem. Additionally, 25\% of those who did not follow the treatmentschedule had not eradicated the parasite, even thoughthey received coartem. Nearly a third of patients were given Coartem without going through malaria testing, according to the data. In adults in Khartoum state, Sudan, the effectiveness of Artemether-Lumefantrine for treating uncomplicated malaria is declining. To determine how often treatments fail and what variables contribute to drugs having less of an effect, prospective trials are required. Pharmacists should not provide antimalarial medication without a doctor's order and a positive blood test for malaria.}
}

⬇ .bib

RIS (EndNote, Zotero, Mendeley)

TY  - JOUR
TI  - Therapeutic Failures in Adult Patients Treated with Artemether-Lumefantrine: A Dual-Sector Analytical Study
AU  - M.Kishore Babu
AU  - B.Sandhya Rani
AU  - I. Triveni
AU  - B.Revathi
JO  - Journal of Science & Technology
PY  - 2025
DA  - 2025/08/02/
VL  - 10
IS  - 08
SP  - 60
EP  - 66
PB  - Longman Publishers
SN  - 2456-5660
LA  - en
AB  - Artemether-Lumefantrine medication is becoming less effective in treating simple cases of malaria in many places where the disease is prevalent. Worldwide, plasmodium falciparum and plasmodium vivax parasite tolerance, recrudescence, and resistance are on the rise. Our objective was to assess the rate of Artemether-Lumefantrine (Coartem) treatment failure in persons presenting with uncomplicated malaria at health facilities. From April 1, 2022, to June 30, 2022, 166 patients with positive malaria test results attended health facilities as part of this descriptive cross-sectional research. A total of 9.6% of malaria patients did not show improvement after receiving corticosteroids; 6.0% had plasmodium falciparum, 2.4% plasmodium vivax, and 1.2 had a mixed infection. Among those who did not take the medication with the fatty meal, 31% tested positive for malaria after two weeks of receiving coartem. Additionally, 25% of those who did not follow the treatmentschedule had not eradicated the parasite, even thoughthey received coartem. Nearly a third of patients were given Coartem without going through malaria testing, according to the data. In adults in Khartoum state, Sudan, the effectiveness of Artemether-Lumefantrine for treating uncomplicated malaria is declining. To determine how often treatments fail and what variables contribute to drugs having less of an effect, prospective trials are required. Pharmacists should not provide antimalarial medication without a doctor's order and a positive blood test for malaria.
DO  - 10.46243/jst.2025.v10.i08.pp60-65
UR  - https://doi.org/10.46243/jst.2025.v10.i08.pp60-65
ER  -

⬇ .ris

CSL-JSON

{
    "type": "article-journal",
    "id": "10.46243/jst.2025.v10.i08.pp60-65",
    "DOI": "10.46243/jst.2025.v10.i08.pp60-65",
    "URL": "https://doi.org/10.46243/jst.2025.v10.i08.pp60-65",
    "title": "Therapeutic Failures in Adult Patients Treated with Artemether-Lumefantrine: A Dual-Sector Analytical Study",
    "source": "Smart Scholars Registry",
    "container-title": "Journal of Science & Technology",
    "author": [
        {
            "family": "M.Kishore Babu"
        },
        {
            "family": "B.Sandhya Rani"
        },
        {
            "family": "I. Triveni"
        },
        {
            "family": "B.Revathi"
        }
    ],
    "issued": {
        "date-parts": [
            [
                2025,
                8,
                2
            ]
        ]
    },
    "volume": "10",
    "issue": "08",
    "page": "60-66",
    "publisher": "Longman Publishers",
    "language": "en",
    "abstract": "Artemether-Lumefantrine medication is becoming less effective in treating simple cases of malaria in many places where the disease is prevalent. Worldwide, plasmodium falciparum and plasmodium vivax parasite tolerance, recrudescence, and resistance are on the rise. Our objective was to assess the rate of Artemether-Lumefantrine (Coartem) treatment failure in persons presenting with uncomplicated malaria at health facilities. From April 1, 2022, to June 30, 2022, 166 patients with positive malaria test results attended health facilities as part of this descriptive cross-sectional research. A total of 9.6% of malaria patients did not show improvement after receiving corticosteroids; 6.0% had plasmodium falciparum, 2.4% plasmodium vivax, and 1.2 had a mixed infection. Among those who did not take the medication with the fatty meal, 31% tested positive for malaria after two weeks of receiving coartem. Additionally, 25% of those who did not follow the treatmentschedule had not eradicated the parasite, even thoughthey received coartem. Nearly a third of patients were given Coartem without going through malaria testing, according to the data. In adults in Khartoum state, Sudan, the effectiveness of Artemether-Lumefantrine for treating uncomplicated malaria is declining. To determine how often treatments fail and what variables contribute to drugs having less of an effect, prospective trials are required. Pharmacists should not provide antimalarial medication without a doctor's order and a positive blood test for malaria.",
    "ISSN": "2456-5660"
}

⬇ .json What citeproc and reference managers read; the DOI system hands it out for Accept: application/vnd.citationstyles.csl+json, and so does this registry's resolver.

From the record as registered (version 2) — the record and its history. Programs: https://registry.smartscholars.in/api.php?action=cite&doi=10.46243%2Fjst.2025.v10.i08.pp60-65 gives all four in one JSON answer.

Share this page

Share this page

Ask AI about this page

Everything Smart Scholars runs

Nine sites, one account. A journal starts at the audit; an author starts at Scholar Shield.

What we do: DOIs registered from what a journal already has · Crossref records completed — references, abstracts, licences, ORCID iDs, affiliations and ROR IDs, funding · DOIs that resolve · articles preserved · journals rated on the public record · see everything we do →

Book a free call

For journals & publishers

Start with the audit — ₹4,999 per journal, and the gate to everything else.

DOI care

Every service on one journal profile — each previews first and acts only on your approval.

  • DOI Doctor — check & repairevery DOI tested at doi.org and Crossref; dead links, abstracts, licences, ORCIDs
  • Smart Deposita new DOI from your PDF, Word file, article page, JATS XML or spreadsheet — every value shown with its source, deposited once you confirm it
  • DOI census (Excel)site against Crossref, both directions, with a copy-paste fix per article
  • Backfile DOIsDOIs for older articles that never had one — no per-DOI fee of ours
  • DOIs for conference proceedingsthe conference, the volume and every paper — registered in the organiser's own name
  • Scopus indexing guidethe minimum criteria, the 14 CSAB criteria and how a title is suggested — from Elsevier's own page
  • Embase indexing guidewhat Embase asks of a biomedical journal and how to suggest it
  • Write DOIs into OJSthe verified DOIs pushed onto your article pages through your own API
  • Silent-failure monitorweekly checks of site, OAI-PMH, Scholar tags, ISSN, preservation, hijack lists
  • Journal Radarevery journal, every day: SSL, DNS, redirects, robots.txt, OJS, DOIs, Crossref metadata, broken links — what broke since yesterday first
  • Verified metrics & badgesa public, dated, source-linked metrics page and a "cited by" badge
  • Quality dossier (PDF)one PDF for universities, authors and reviewers
  • Author citation enginethe citation steps emailed to each author from the journal's own mailbox
  • JATS XMLmachine-readable JATS per article
  • Duplicate articlesthe same paper published twice — you choose which copy stays

For authors & researchers

Free to use. Nothing you check is shared with the journal.

For institutions, sponsors & DOI operators

Smart Scholars

Mon–Sat, 10:00–19:00 IST. The Ask AI button on every page answers about our services at any hour.

News

Policies

What we can register a DOI for

20 kinds of record, one account, one place. Every one gets a DOI that resolves, metadata that indexes read, and a record that stays correct afterwards.

Journals

  • Journal articles
  • Journal titles
  • Pending publications
  • Peer reviews
  • Preprints & posted content

Books & conferences

  • Books
  • Book chapters
  • Book series
  • Book sets
  • Conference proceedings
  • Proceedings series
  • Conference papers

Other research output

  • Theses & dissertations
  • Reports & working papers
  • Report series
  • Standards
  • Databases
  • Datasets
  • Figures, tables & supplements

Funding

  • Grants & funding awards

Elsewhere

The same company, in the places our publishers already read.
Add Smart Scholars as a preferred source on GoogleSee more of our newsroom in Google’s Top Stories.
Smart Scholars · Every service on one pageNewsroom posts CC BY 4.0 · DOI metadata CC0 · everything else ©Data from OpenAlex (openalex.org), CC0 · Crossref · ISSN Portal · DOAJContact
WhatsApp